Podcasts about disease modifying therapies

Welcome to Living Well with MS, the podcast that empowers you to take control of your health and wellbeing. Today we're thrilled to welcome Yvette Sargood as our guest! Yvette is an Overcoming MS facilitator and a meditation teacher who lives with MS and follows the Overcoming MS program. In this fascinating episode, Yvette talks to Geoff about meditation and mindfulness, as well as her personal journey with the MS Program, including disclosing her diagnosis to her employer and how she overcame her chocolate cravings! There's lots of useful information and tips in this episode (including a discussion on chocolate replacements!) We hope you enjoy it – let us know what you think! Watch this episode on YouTube here. Keep reading for the key episode takeaways.   Topics and Timestamps: 01:18 Yvette's MS and Overcoming MS journey 07:05 The progress made on DMTs and discrimination since the 1990s 09:01 The benefits to starting the Overcoming MS program even long after diagnosis 11:26 The decision to start a disease modifying therapy 14:59 Her difficulties in adopting the Overcoming MS program 16:27 Overcoming her chocolate cravings and chocolate replacements 18:51 Maintaining a healthy weight on the Overcoming MS program 20:23 The benefits of following the Overcoming MS program 22:54 Disclosing a multiple sclerosis diagnosis to your employer 26:01 Becoming an Overcoming MS facilitator 27:46 What is mindfulness and why is it important for people with MS? 32:53 Misconceptions about meditation and stress reduction 35:42 Tips for people new to the Overcoming MS program   Want to learn more about living a full and happy life with multiple sclerosis?  Sign up to our newsletter to hear our latest tips. More info and links: Download the Headspace app for meditation Learn more about Disease Modifying Therapies for MS Listen to a podcast featuring OMSer chef Read Yvette's article on executives and disability Learn more about mindfulness expert Jon Kabat-Zinn Join a mindfulness course with Yvette through MS-UK Become an Overcoming MS volunteer To take part in the next Pathway to Overcoming MS course email events@overcomingms.org New to Overcoming MS? Visit our introductory page Connect with others following Overcoming MS on the Live Well Hub Visit the Overcoming MS website Follow us on social media: Facebook Instagram YouTube Pinterest Don't miss out:  Subscribe to this podcast and never miss an episode. Listen to our archive of Living Well with MS episodes here. If you like Living Well with MS, please leave a 5-star review. Feel free to share your comments and suggestions for future guests and episode topics by emailing podcast@overcomingms.org. Make sure you sign up to our newsletter to hear our latest tips and news about living a full and happy life with MS. Support us:  If you enjoy this podcast and want to support the ongoing work of Overcoming MS, we would really appreciate it if you could leave a donation here. Every donation, however small, helps us to share the podcast with more people on how to live well with MS.

CME credits: 1.00 Valid until: 25-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/therapeutic-insights-navigating-the-use-and-challenges-of-disease-modifying-therapies/26346/ This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer's disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer's disease.

CME credits: 1.00 Valid until: 25-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/breaking-ground-the-latest-data-on-ad-disease-modifying-therapies/26345/ This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer's disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer's disease.

CME credits: 1.00 Valid until: 10-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/spinal-muscular-atrophy-optimizing-the-management-of-adults-in-the-era-of-disease-modifying-therapies/26352/ Explore this on-demand webcast for an in-depth expert presentation and case discussion. This educational initiative is designed to help neurologists enhance their clinical approach by providing individualized, evidence-based care for adult SMA patients. Gain insights into the latest treatment options, safety and efficacy data, and effective patient communication strategies. Equip yourself with the knowledge to meet the unique clinical and psychosocial needs of adults with SMA and improve patient outcomes.=

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AMU865. CME credit will be available until April 2, 2025.Navigating Advances in Alzheimer's Disease: An Expert Consult on Integrating the New Diagnostic Tools and Disease-Modifying Therapies Into Your Clinical Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Eisai Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AMU865. CME credit will be available until April 2, 2025.Navigating Advances in Alzheimer's Disease: An Expert Consult on Integrating the New Diagnostic Tools and Disease-Modifying Therapies Into Your Clinical Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Eisai Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AMU865. CME credit will be available until April 2, 2025.Navigating Advances in Alzheimer's Disease: An Expert Consult on Integrating the New Diagnostic Tools and Disease-Modifying Therapies Into Your Clinical Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Eisai Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AMU865. CME credit will be available until April 2, 2025.Navigating Advances in Alzheimer's Disease: An Expert Consult on Integrating the New Diagnostic Tools and Disease-Modifying Therapies Into Your Clinical Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Eisai Inc.Disclosure information is available at the beginning of the video presentation.

When people living with MS find themselves unable to continue working due to disability, they turn to Social Security Disability Insurance (SSDI). And when they do, many are surprised to find the long, winding, sometimes confusing road that lies ahead.  This week, disability law expert Jamie Hall joins me to demystify the process of applying for SSDI benefits. Jamie specializes in social security and long-term disability law. And he, literally, wrote the book for the National MS Society on applying for SSDI benefits. We'll also tell you about the amazing work this year's recipient of the Barancik Prize for Innovation in MS Research is involved in. We're reporting on the progress that scientists are making in penetrating the blood brain barrier (And we'll remind you about why that makes a real difference for everyone living with MS!) We're sharing the details about KYV-101, the experimental CAR-T cell therapy that's been given a Fast Track designation by the FDA. We'll tell you about study results that show people with a university education are more likely to be on a disease-modifying therapy. And we're sharing study results that identify the inequity in geographic proximity to MS care in the United States. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: How to apply for Social Security Disability Insurance benefits  :22 This year's recipient of the Barancik Prize for Innovation in MS research  1:58 Real progress reported in efforts to penetrate the blood brain barrier  7:17 FDA gives Fast-Track designation to CAR-T cell therapy for MS  10:03 STUDY: Having a university education makes it more likely that someone with MS will be on a DMT  13:04 STUDY: Geographic proximity to MS care in the U.S. is far from equal   15:04 Disability law expert Jamie Hall discusses how to apply for SSDI benefits   19:29 Share this episode  38:01 Have you downloaded the free RealTalk MS app?  38:21 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/336 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Applying for Social Security Disability Benefits: A Guidebook for People with MS and their Healthcare Providers https://nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/Guidebook-Social-Security-Disability-for-People-with-MS.pdf Predictive High-Throughput Platform for Dual Screening of mRNA Lipid Nanoparticle Blood Brain Barrier Transfection and Crossing https://pubs.acs.org/doi/10.1021/acs.nanolett.3c03509 STUDY: University Education Facilitates Uptake of Disease-Modifying Therapies for Multiple Sclerosis: A Community-Based Study Using the UK MS Register https://journals.sagepub.com/doi/10.1177/13524585231221411 STUDY: Geographic Proximity in Access to Neurologists and Multiple Sclerosis Care in the United States https://www.neurology.org/doi/10.1212/WNL.0000000000207916 Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 336 Guest: Jamie Hall, Esq. Privacy Policy

Hosts discuss a recent study on baricitinib in type 1 diabetes, how these results compare to other data in this arena, and what all of these studies mean for future of type 1 diabetes management. Episode Highlights 00:05 Intro 01:20 Baricitinib Overview 02:30 BANDIT Trial Design 03:30 Trial Results 05:40 Delaying Type 1 Diabetes 14:45 Need for Screening 18:00 Outro

Barbara S. Giesser, MD, FAAN, FANA, is an internationally recognized clinician and award-winning educator who has specialized in the care of persons with Multiple Sclerosis since 1982. Her approach to the diagnosis and management of persons with MS combines advanced diagnostics and a personalized medication plan for each patient with an emphasis on integrating lifestyle and wellness strategies into the neurologic treatment plan. Learn about disease modifying therapies for the treatment of Multiple Sclerosis in this PNI Minute.For more information: 310-582-7613 | pacificbrainhealth.org

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jay Avasarala, MD, PhD The three disease-modifying therapies for MS added into the World Health Organization's (WHO) Essential Medicines list is a great step forward for patients afflicted with this chronic disease and could also serve as a model for other neurological disorders. Dive in as Dr. Charles Turck talks to one member of the team who was responsible for submitting this list of medications, Dr. Jay Avasarala, Director of Comprehensive Care Center for Multiple Sclerosis and Neuroimmunology at the Kentucky Neuroscience Institute in Lexington.

CME credits: 1.00 Valid until: 08-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/novel-and-emerging-disease-modifying-therapies-for-mild-cognitive-impairment-due-to-ad-efficacy-and-safety-of-new-dmts-for-mci/16055/ New data and emerging science have significantly advanced our understanding of the pathophysiology of mild cognitive impairment (MCI) and early-onset Alzheimer's disease (AD). The FDA has recently approved new disease-modifying therapies (DMTs) that slow the clinical course of MCI caused by AD. This curriculum helps clinicians identify the subtle signs and symptoms of MCI in AD. The program also helps clinicians recognize why and how racial and ethnic differences and disparities affect DMT acceptance, patient outcomes, and disease onset and progression. Faculty discuss the emerging data surrounding the novel pathways and mechanisms that drive MCI in AD and outline evidence-based treatment strategies as well as how to incorporate the new DMTs into clinical practice.

In this episode of The Just M.S. Show, we delve into the remarkable advances in the world of Multiple Sclerosis (MS) treatment and detection. From AI models predicting MS risk before symptoms appear to the groundbreaking addition of MS medications to WHO's Essential Medicines List, the hope for effective treatment is brighter than ever. We discuss the efficacy of ocrelizumab as a first-line treatment and the shift in disease-modifying therapy prescription towards oral medications. We also share personal stories of aging with MS, and the interplay between MS progression and normal aging processes. Finally, we explore fascinating research insights on how gut microbiome could trigger MS onset, and how Biogen's acquisition of Reata Pharmaceuticals might shape the future of rare disease treatments. Join us for these discussions and more as we navigate through the dynamic landscape of MS research, treatment, and personal experiences.Intro – Justin kicks off the episode by introducing the listeners to the engaging content of the day which includes the latest breakthroughs in Multiple Sclerosis (MS) treatment, research, and personal experiences.AI in Healthcare – Justin dives deep into a PRNewswire article highlighting the role of artificial intelligence (AI) and machine learning in predicting MS and minimizing laboratory errors.https://www.prnewswire.com/news-releases/artificial-intelligence-models-predict-multiple-sclerosis-detect-contaminated-lab-samples-301883543.htmlEssential Medicines Update – Discussion on the World Health Organization's new additions to the Model Lists of Essential Medicines for MS treatment, providing an analysis of how this could influence the lives of patients across the globe.https://www.who.int/news/item/26-07-2023-who-endorses-landmark-public-health-decisions-on-essential-medicines-for-multiple-sclerosisOcrelizumab Efficacy – Detailed analysis of a Healio article revealing the effectiveness of ocrelizumab as a first-line treatment for MS, backed by a comprehensive 9-year research study.https://www.healio.com/news/neurology/20230726/video-ocrelizumab-effective-as-firstline-treatment-for-msAging with MS – In this heartfelt segment, Justin presents the narrative of Trevis Gleason from Everyday Health, where he shares his personal journey with aging and MS, which many listeners will relate to.https://www.everydayhealth.com/columns/trevis-gleason-life-with-multiple-sclerosis/aging-with-ms/Prescription Shifts – Delving into a study from HealthDay News, Justin discusses the noticeable shift towards oral disease-modifying therapies in MS treatment.Gut Microbiome and MS – An exciting segment discussing research from Ludwig-Maximilians-Universität München about the relationship between the gut microbiome and the activation of auto-aggressive T cells in MS.Biogen and Reata Acquisition – In the final part of the episode, Justin tackles Biogen's recent acquisition of Reata Pharmaceuticals, offering insights into how this might shape the future of the rare disease drugs market, including MS treatment.https://www.washingtonpost.com/business/2023/07/28/biogen-deal-for-reata-signals-a-turn-to-rare-diseases/9cbf4a84-2d67-11ee-a948-a5b8a9b62d84_story.htmlOutro – Wrapping up, Justin encourages the listeners to stay positive, informed, and connected, and invites them to join the next episode of "The Just M.S. Show".Listeners are encouraged to refer to the episode description for linkThe Just MS (Multiple Sclerosis) Show, w host Justin Loizos, is a podcast that connects, educates and tries to uplift others living with multiple sclerosis. It provides real-life stories, interviews, and information about DMTs (disease modification therapies) and updates on research developments.www.justmultiplesclerosis.com

Dr. Katz is the Director of the Elliot Lewis Center, and a nationally recognized expert in multiple sclerosis, neuromyelitis optica, MOG associated disease, and transverse myelitis. I've worked alongside Dr. Katz for many years and shared many patients. He's one of the few neurologists who truly listens to you and your symptoms and will spend the time to brainstorm solutions for living your best life with MS. Not only that, the Elliot Lewis Center provides cutting-edge care and access to all of the available therapeutic options and strategies. On today's episode, Dr. Katz talks about the newest disease-modifying therapy for MS, Briumvi. He shares what it is, how it works, its efficacy, how it compares to other available DMT's. Connect with Dr. Katz: Website: https://elliotlewisms.com/about-us/ Facebook: https://www.facebook.com/ElliotLewisMS Additional Resources: https://www.doctorgretchenhawley.com/insider Reach out to Me: hello@doctorgretchenhawley.com Website: www.MSingLink.com Social: ★ Facebook: https://www.facebook.com/groups/mswellness ★ Instagram: https://www.instagram.com/doctor.gretchen ★ YouTube: https://www.youtube.com/c/doctorgretchenhawley?sub_confirmation=1 → Game Changers Course: https://www.doctorgretchenhawley.com/GameChangersCourse → Total Core Program: https://www.doctorgretchenhawley.com/TotalCoreProgram → The MSing Link: https://www.doctorgretchenhawley.com/TheMSingLink

Robbie Gillett was at work when he became unable to move as he was installing a kitchen unit. He was convinced that he was dying or having a stroke but eventually, he was diagnosed with Multiple Sclerosis - twice!As a way to process his new reality, Robbie began writing poetry, which has been published in his first collection, Thoughts of a Warrior: Beneath the Tracksuit.In the first part of a two-part interview, Robbie talks about his journey to a definitive diagnosis, his initial experiences with Disease Modifying Therapies, and the process of finding a supportive community online.Links and resources:Connect with Robbie on Instagram, Twitter, and FacebookBuy Robbie's book, Thoughts of a Warrior: Beneath the Tracksuit Watch The Painter And The Poet on YouTube Listen to Robbie's music on SpotifyIf you're interested in having Kathy speak at your event, learn more hereFind out more about the DMAT Fitness Training programYou can find Kathy Chester at:msdisrupted@gmail.comdisruptfitnessgym@gmail.com moveitorloseit109@gmail.com Connect with @msdisrupted on Instagram, Facebook, TikTok Here are some additional products that help Kathy deal with beating the Heat and Migraines.  Take advantage of the coupon code.Koldtec - Cool Head WrapKOLD10To save $10 off every item in-store.2 items = $20 savings3 items = $30 savingshttps://www.koldtec.com/ Cold bean bag Releafpack. 15% discount use code Disrupt15https://www.releafpack.com 

ORAL MINOXIDIL IN PEDIATRICS   Jerjen R et al (starts at 12:33). Low-dose oral minoxidil improves global hair density and length in children with loose anagen hair syndrome. Br J Dermatol. 2021;184(5):977-978. Nicolas-Ruanes et al (starts at 15:33). Low-dose oral minoxidil for treatment of androgenetic alopecia and telogen effluvium in a pediatric population: A descriptive study. J Am Acad Dermatol. 2022 Apr 26; John JM et al (starts at 17:24). Safety and tolerability of low-dose oral minoxidil in adolescents: A retrospective review. J Am Acad Dermatol . 2022 Jul 5;S0190-9622(22)02245-9.   HAIR FIBERS AND CAMOUFLAGE Ring and Keller (starts at 25:13). Effect of camouflaging agents on psychologic well-being: A cross-sectional survey of hair loss patients. J Am Acad Dermatol. 2017 Jun;76(6):1186-1189 Babadjouni A et al (starts at 28:15). Patient Satisfaction and Adverse Effects Following the use of Topical Hair Fiber Fillers. Int J Trichology. 2022 May-Jun; 14(3): 97–102   HYDROXYCHLOROQUINE IN PREGNANCY Reynolds JA et al (starts at 34:38). Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine. Rheumatology (Oxford). 2022 Jun 29: Sperber K et al (starts at 38:25). Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases. Pediatr Rheumatol Online J 2009;7:9. Kaplan Y et al (starts at 39:17). Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016 May;81(5):835-48. Clowse MEB et al (starts at 40:27). Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data. Lupus Sci Med. 2022 Mar;9(1):e000651. Huybrechts K et al (starts at 42:37). Hydroxychloroquine early in pregnancy and risk of birth defects. Am J Obstet Gynecol 2021 Mar;224(3):290.e1-290.e22 Huybrechts K et al (starts at 45:20). Hydroxychloroquine early in pregnancy and risk of birth defects: absence of evidence is not the same as evidence of absence. Am J Obstet Gynecol. 2021 May;224(5):549-550. Bérard et al (starts at 46:58). Chloroquine and Hydroxychloroquine Use During Pregnancy and the Risk of Adverse Pregnancy Outcomes Using Real-World Evidence. Front Pharmacol. 2021 Aug 2;12:722511. Howley et al (starts at 47:17). Maternal exposure to hydroxychloroquine and birth defects. Birth Defects Res. 2021 Oct 15;113(17):1245-1256. Andersson et al (starts at 47:34). Fetal safety of chloroquine and hydroxychloroquine use during pregnancy: a nationwide cohort study. Rheumatology (Oxford). 2021 May 14;60(5):2317-2326.   TERIFLUNOMIDE INDUCED HAIR LOSS IN MULTIPLE SCLEROSIS Travis LH et al (starts at 53:28). Real-World Observational Evaluation of Hair Thinning in Patients with Multiple Sclerosis Receiving Teriflunomide: Is It an Issue in Clinical Practice? Neurol Ther. 2018 Dec; 7(2): 341–347. Porwal MH et al (starts at 55:41). Alopecia in Multiple Sclerosis Patients Treated with Disease Modifying Therapies. J Cent Nerv Syst Dis. 2022 Jun 23;14:11795735221109674.   DO IT YOURSELF LOW-ALLERGEN PRODUCTS Xiong M and Warshaw EM. (starts at 1:05:45) Hair Care Product Hacks: Do It Yourself Alternatives. Dermatitis. 2022 Jun 29. Zirwas M and Moennich J (starts at 1:00:25). Shampoos. Dermatitis. 2009 Mar-Apr;20(2):106-10 Tawfik M, Rodriguez-Homs LG, Alexander T, et al (starts at 1:01:10). Allergen content of  best-selling ethnic versus nonethnic shampoos, conditioners, and styling products. Dermatitis 2021;32(2):101–110 https://donovanmedical.com/diy   PREMATURE GREYING (EARLY CANITIES) Anggraini et al (starts at 1:08:50). Risk Factors Associated with Premature Hair Greying of Young Adult. Open Access Maced J Med Sci . 2019 Nov 14;7(22):3762-3764. Dawber RP (starts at 1:09:12). Integumentary associations of pernicious anaemia. Br J Dermatol . 1970 Mar;82(3):221-3. Mosley JG and Gibbs AC (starts at 1:09:50). Premature grey hair and hair loss among smokers: a new opportunity for health education? British Medical Journal 1996; 313: 1616. Bhat RM et al (starts at 1:10:21). Epidemiological and investigative study of premature graying of hair in higher secondary and pre-university school children. Int J Trichology. 2013;5:17–21. Chang H-C and Sung C-W (starts at 1:10:35). Association between serum levels of minerals and premature hair graying: a systematic review and meta-analysis. Int J Dermatol. 2020 Oct;59(10):e378-e380. Schnohr P et al (starts at 1:12:35). Longevity and gray hair, baldness, facial wrinkles, and arcus senilis in 13,000 men and women: The Copenhagen city heart study. J Gerontol A Biol Sci Med Sci. 1998;53:M347–50. Schnohr P et al. Gray hair, baldness, and wrinkles in relation to myocardial infarction: the Copenhagen City Heart Study. Am Heart J  1995 Nov;130(5):1003-10.   Kocaman SA et al (starts at 1:14:10) . The degree of premature hair graying as an independent risk marker for coronary artery disease: A predictor of biological age rather than chronological age. Anadolu Kardiyol Derg 2012;12:457-63.  Paik S et al (starts at 1:14:25). Association Between Premature Hair Greying and Metabolic Risk Factors: A Cross-sectional Study. Acta Derm Venereo. 2018 Aug 29;98(8):748-752. Mahendiratta S et al (starts at 1:15:09). Premature graying of hair: Risk factors, co-morbid conditions, pharmacotherapy and reversal-A systematic review and meta-analysis. Dermatol Ther. 2020 Nov;33(6):e13990. Das S et al (starts at 1:15:51) Cardiovascular risk markers in premature canities. Indian J Dermatol Venereol Leprol. 2022 Jun 30;1-5.

Join our conversation to hear how a toxin that's commonly used for cosmetic purposes is a game changer for Jennifer in managing her MS-induced neurogenic bladder. She had her second-ever Botox treatment on July 12, and these treatments have given her increased urinary continence and confidence. And this twice-a-year procedure is just one way Jennifer is showing this disease who's boss. Listen to learn what led her to consider this form of treatment, how her previous experiences with MS disease-modifying therapies instilled the confidence to move forward with Botox, and what her advice is for anybody with MS who is looking into this option for treating MS-related incontinence issues.

Go online to PeerView.com/YFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in neurology discuss advances in the early treatment of Alzheimer's disease, including novel biomarkers and emerging disease-modifying therapies. Upon completion of this activity, participants should be better able to: Integrate novel biomarkers for the early detection and treatment of AD based on the latest evidence, Apply the latest clinical data on emerging treatments that target the underlying pathology of AD.

Go online to PeerView.com/YFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in neurology discuss advances in the early treatment of Alzheimer's disease, including novel biomarkers and emerging disease-modifying therapies. Upon completion of this activity, participants should be better able to: Integrate novel biomarkers for the early detection and treatment of AD based on the latest evidence, Apply the latest clinical data on emerging treatments that target the underlying pathology of AD.

Go online to PeerView.com/YFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in neurology discuss advances in the early treatment of Alzheimer's disease, including novel biomarkers and emerging disease-modifying therapies. Upon completion of this activity, participants should be better able to: Integrate novel biomarkers for the early detection and treatment of AD based on the latest evidence, Apply the latest clinical data on emerging treatments that target the underlying pathology of AD.

Go online to PeerView.com/YFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in neurology discuss advances in the early treatment of Alzheimer's disease, including novel biomarkers and emerging disease-modifying therapies. Upon completion of this activity, participants should be better able to: Integrate novel biomarkers for the early detection and treatment of AD based on the latest evidence, Apply the latest clinical data on emerging treatments that target the underlying pathology of AD.

Go online to PeerView.com/YFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in neurology discuss advances in the early treatment of Alzheimer's disease, including novel biomarkers and emerging disease-modifying therapies. Upon completion of this activity, participants should be better able to: Integrate novel biomarkers for the early detection and treatment of AD based on the latest evidence, Apply the latest clinical data on emerging treatments that target the underlying pathology of AD.

Go online to PeerView.com/YFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in neurology discuss advances in the early treatment of Alzheimer's disease, including novel biomarkers and emerging disease-modifying therapies. Upon completion of this activity, participants should be better able to: Integrate novel biomarkers for the early detection and treatment of AD based on the latest evidence, Apply the latest clinical data on emerging treatments that target the underlying pathology of AD.

Go online to PeerView.com/YFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in neurology discuss advances in the early treatment of Alzheimer's disease, including novel biomarkers and emerging disease-modifying therapies. Upon completion of this activity, participants should be better able to: Integrate novel biomarkers for the early detection and treatment of AD based on the latest evidence, Apply the latest clinical data on emerging treatments that target the underlying pathology of AD.

Go online to PeerView.com/YFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in neurology discuss advances in the early treatment of Alzheimer's disease, including novel biomarkers and emerging disease-modifying therapies. Upon completion of this activity, participants should be better able to: Integrate novel biomarkers for the early detection and treatment of AD based on the latest evidence, Apply the latest clinical data on emerging treatments that target the underlying pathology of AD.

Go online to PeerView.com/JCU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in complement 3 glomerulopathy (C3G) discusses evidence-based approaches to differentially diagnose patients with C3G and reviews the evidence for current and emerging treatment strategies. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of C3G, highlighting the rationale for using complement proteins and proteinuria as therapeutic targets, Differentially diagnose patients with C3G using evidence-based tools and strategies, Identify the mechanisms of action for agents targeted at specific complement inhibitors (eg, Factors B, C5a, C3, etc), Incorporate the latest findings for approved and emerging pharmacotherapies to optimize the management of patients with C3G.

Go online to PeerView.com/JCU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in complement 3 glomerulopathy (C3G) discusses evidence-based approaches to differentially diagnose patients with C3G and reviews the evidence for current and emerging treatment strategies. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of C3G, highlighting the rationale for using complement proteins and proteinuria as therapeutic targets, Differentially diagnose patients with C3G using evidence-based tools and strategies, Identify the mechanisms of action for agents targeted at specific complement inhibitors (eg, Factors B, C5a, C3, etc), Incorporate the latest findings for approved and emerging pharmacotherapies to optimize the management of patients with C3G.

Go online to PeerView.com/JCU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in complement 3 glomerulopathy (C3G) discusses evidence-based approaches to differentially diagnose patients with C3G and reviews the evidence for current and emerging treatment strategies. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of C3G, highlighting the rationale for using complement proteins and proteinuria as therapeutic targets, Differentially diagnose patients with C3G using evidence-based tools and strategies, Identify the mechanisms of action for agents targeted at specific complement inhibitors (eg, Factors B, C5a, C3, etc), Incorporate the latest findings for approved and emerging pharmacotherapies to optimize the management of patients with C3G.

Go online to PeerView.com/JCU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in complement 3 glomerulopathy (C3G) discusses evidence-based approaches to differentially diagnose patients with C3G and reviews the evidence for current and emerging treatment strategies. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of C3G, highlighting the rationale for using complement proteins and proteinuria as therapeutic targets, Differentially diagnose patients with C3G using evidence-based tools and strategies, Identify the mechanisms of action for agents targeted at specific complement inhibitors (eg, Factors B, C5a, C3, etc), Incorporate the latest findings for approved and emerging pharmacotherapies to optimize the management of patients with C3G.

Go online to PeerView.com/JCU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in complement 3 glomerulopathy (C3G) discusses evidence-based approaches to differentially diagnose patients with C3G and reviews the evidence for current and emerging treatment strategies. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of C3G, highlighting the rationale for using complement proteins and proteinuria as therapeutic targets, Differentially diagnose patients with C3G using evidence-based tools and strategies, Identify the mechanisms of action for agents targeted at specific complement inhibitors (eg, Factors B, C5a, C3, etc), Incorporate the latest findings for approved and emerging pharmacotherapies to optimize the management of patients with C3G.

Go online to PeerView.com/JCU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in complement 3 glomerulopathy (C3G) discusses evidence-based approaches to differentially diagnose patients with C3G and reviews the evidence for current and emerging treatment strategies. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of C3G, highlighting the rationale for using complement proteins and proteinuria as therapeutic targets, Differentially diagnose patients with C3G using evidence-based tools and strategies, Identify the mechanisms of action for agents targeted at specific complement inhibitors (eg, Factors B, C5a, C3, etc), Incorporate the latest findings for approved and emerging pharmacotherapies to optimize the management of patients with C3G.

Go online to PeerView.com/JCU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in complement 3 glomerulopathy (C3G) discusses evidence-based approaches to differentially diagnose patients with C3G and reviews the evidence for current and emerging treatment strategies. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of C3G, highlighting the rationale for using complement proteins and proteinuria as therapeutic targets, Differentially diagnose patients with C3G using evidence-based tools and strategies, Identify the mechanisms of action for agents targeted at specific complement inhibitors (eg, Factors B, C5a, C3, etc), Incorporate the latest findings for approved and emerging pharmacotherapies to optimize the management of patients with C3G.

Go online to PeerView.com/JCU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in complement 3 glomerulopathy (C3G) discusses evidence-based approaches to differentially diagnose patients with C3G and reviews the evidence for current and emerging treatment strategies. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of C3G, highlighting the rationale for using complement proteins and proteinuria as therapeutic targets, Differentially diagnose patients with C3G using evidence-based tools and strategies, Identify the mechanisms of action for agents targeted at specific complement inhibitors (eg, Factors B, C5a, C3, etc), Incorporate the latest findings for approved and emerging pharmacotherapies to optimize the management of patients with C3G.

Go online to PeerView.com/JCU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in complement 3 glomerulopathy (C3G) discusses evidence-based approaches to differentially diagnose patients with C3G and reviews the evidence for current and emerging treatment strategies. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of C3G, highlighting the rationale for using complement proteins and proteinuria as therapeutic targets, Differentially diagnose patients with C3G using evidence-based tools and strategies, Identify the mechanisms of action for agents targeted at specific complement inhibitors (eg, Factors B, C5a, C3, etc), Incorporate the latest findings for approved and emerging pharmacotherapies to optimize the management of patients with C3G.

Go online to PeerView.com/JCU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in complement 3 glomerulopathy (C3G) discusses evidence-based approaches to differentially diagnose patients with C3G and reviews the evidence for current and emerging treatment strategies. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of C3G, highlighting the rationale for using complement proteins and proteinuria as therapeutic targets, Differentially diagnose patients with C3G using evidence-based tools and strategies, Identify the mechanisms of action for agents targeted at specific complement inhibitors (eg, Factors B, C5a, C3, etc), Incorporate the latest findings for approved and emerging pharmacotherapies to optimize the management of patients with C3G.

Dr. Daniel Hartung discusses the association between Medicare Part D Plan disease-modifying therapy restrictiveness and adherence and outcomes among people with multiple sclerosis. Show references: https://cp.neurology.org/content/12/1/36 https://www.neurology.org/podcast

Dr. Justin Abbatemarco talks with Dr. Daniel Hartung about the impact of Medicare Part D plan disease-modifying therapy restrictiveness upon adherence and outcomes among patients with multiple sclerosis. Read the full article in Neurology: Clinical Practice.

I'm delighted that my guests today are Tamara Kahn and Terry Hord, twin sisters who both have MS. Following their diagnosis, they have been navigating their lives with secondary Progressive MS and advocating through work for the National MS Society, their Twins Coast 2 Coast website, and on Instagram.In the first of a two-part interview, they talk about being diagnosed with the same chronic illness, married life, changes they've seen in Disease Modifying Therapies, and how their advocacy work is inspired by their mother's death from a rare form of cancer. The resilience she showed is a legacy that lives on, not only through Tamara and Terry but their own children. Links and resources:Visit Tamara and Terry at Twins Coast 2 CoastVisit the National MS Society and find out more about the Navigator Program You can find Kathy Chester atdisruptfitnessgym@gmail.com moveitorloseit109@gmail.com Instagram - @msmoveitorloseit @disruptfitnessgymHere are some additional products that help Kathy deal with beating the Heat and Migraines.  Take advantage of the coupon code.Koldtec - Cool Head WrapKOLD10To save $10 off every item in store.2 items = $20 savings3 items = $30 savingshttps://www.koldtec.com/ Cold bean bag Releafpack. 15% discount use code Disrupt15https://www.releafpack.com 

If you're living with MS, you know by now that quitting smoking, getting exercise, and making smart food choices have all been shown to improve your physical health and your quality of life. There's one more tool that, when necessary, can be a game-changer.  Joining me to talk about how assistive technology can help people living with MS maintain their independence and improve their quality of life are assistive technology experts Alex Burnham and Bill Binko.  We'll also share one more reason why your most important preparation for the holiday season this year is making sure you're fully vaccinated. We'll tell you about the International Progressive MS Alliance's proposal for coordinating global progressive MS research. We'll share the results of a study that shows a significant percentage of older people living with MS who discontinue their DMT experience disease worsening and progression. We'll tell you about a new grant that's been awarded to study adherence to MS oral disease-modifying therapies. And you'll hear about the results of a study that shows an association between low levels of vitamin D and cognitive dysfunction at the onset of MS. We have a lot to talk about! Are you ready for RealTalk MS??! There's a new reason to be vaccinated!  3:43 International Progressie MS Alliance's proposal for a global progressive MS research agenda   6:57 My goodbye to the Progressive MS Alliance Scientific Steering Committee  8:16 A study shows that older people who discontinue DMTs suffer disease worsening and progression  9:56 Researcher receives $100,000 to study MS oral DMT adherence  12:39 A study shows low levels of Vitamin D are associated with cognitive dysfunction at the onset of MS  15:22 Alex Burnham and Bill Binko discuss how assistive technology can be a difference-maker for people living with MS   18:51 Share this episode  37:47 Have you downloaded the free RealTalk MS app???  38:08 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/223 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com National MS Society COVID-19 Vaccine Guidance for People Living with MS https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance National MS Society Third COVID-19 Vaccine Dose Guidance for People Living with MS https://www.nationalmssociety.org/About-the-Society/News/Additional-COVID-19-Vaccine-Dose-(Booster)-and-MS Charting a Global Research Strategy for Progressive MS -- An International Progressive MS Alliance Proposal https://journals.sagepub.com/doi/10.1177/13524585211059766 STUDY: Discontinuation of Disease-Modifying Therapies is Associated with Disability Progression Regardless of Prior Stable Disease and Agehttps://www.msard-journal.com/article/S2211-0348(21)00673-8/fulltext STUDY: Real World Adherence To, and Persistence With, Once- and Twice-Daily Oral Disease Modifying Drugs in Patients with Multiple Sclerosis: A Systematic Review and Meta-Analysishttps://bmcneurol.biomedcentral.com/articles/10.1186/s12883-020-01830-0 STUDY: Serum Vitamin D as a Marker of Impaired Information Processing Speed and Early Disability in Multiple Sclerosis Patientshttps://www.mdpi.com/2076-3425/11/11/1521/htm Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 223 Guests: Alex Burnham and Bill Binko Tags: MS, MultipleSclerosis, MSResearch, MSSociety, RealTalkMS Privacy Policy

Summertime traditionally means getting out of the house, enjoying outdoor activities, and being active. But if you're living with MS, outdoor activity and summertime temperatures can raise red flags when it comes to your day-to-day quality of life. My guest is Dr. Colin Lenington, an Occupational Therapist and Clinical Specialist at the VA Long Beach Healthcare System and we're talking about getting outside, staying safe, and keeping cool while you enjoy your summer activities. We're joining the World Federation of Neurology and the global MS community on July 22nd, to celebrate World Brain Day 2021. This year's theme is Stop Multiple Sclerosis and we'll tell you where and how to register for the upcoming World Brain Day webinar. We're also talking about study results that show the impact of delaying an Ocrevus infusion in order to enhance the effect of a COVID-19 vaccination. We'll tell you about a study in the U.K. that followed 120 people with MS who received autologous hematopoietic stem cell transplantation (aHSCT). We'll share news about a new way to successfully cross the blood-brain barrier and deliver medicines to the central nervous system. (And we'll explain why that matters when it comes to treating MS) And we'll tell you about a study of veterans with MS that should convince anyone to adhere to their DMT treatment plan. We have a lot to talk about! Are you ready for RealTalk MS??! July 22nd is World Brain Day!  :22 My live conversation with Dr. Victoria Leavitt takes place this Wednesday, on the eSupport Health Wednesday Workshop   :55 Study shows the effect of extended interval dosing of Ocrevus  2:46 Study shows real-world outcomes for 120 people with MS who received aHSCT  5:49 Biopharmaceutical company successfully delivers an anti-inflammatory molecule across the blood-brain barrier  7:43 Study shows the benefits of adhering to DMTs  9:03 Dr. Colin Lenington talks about how to enjoy summertime activities while staying safe and staying cool  11:24 Share this episode  24:25 Catch my live conversation with Dr. Victoria Leavitt on Wednesday  24:48 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/203 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com National MS Society COVID-19 Vaccine Guidance for People Living with MS https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance World Brain Day 2021 https://wfneurology.org/world-brain-day-2021 Register for the eSupport Health Wednesday Workshop: A Conversation with Jon Strum https://esupporthealth.zoom.us/meeting/register/tJEpc--rqT0vHdJ6FbPDH7S1enOrLYAIQG-K STUDY: Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19https://nn.neurology.org/content/8/5/e1035 STUDY: Autologous Haematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: A Real-World Case Serieshttps://n.neurology.org/content/early/2021/07/12/WNL.0000000000012449 Bioasis Announces Positive Results from Efficacy Study of xB3TM -1L-1RA in a Model of Multiple Sclerosis https://www.globenewswire.com/news-release/2021/07/07/2259430/0/en/Bioasis-Announces-Positive-Results-From-an-Efficacy-Study-of-xB3-IL-1RA-in-a-Model-of-Multiple-Sclerosis.html STUDY: The Impact of Adherence to Disease-Modifying Therapies on Functional Outcomes in Veterans with Multiple Sclerosis https://journals.sagepub.com/doi/pdf/10.1177/11795735211028769 Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Androidhttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 203 Guest: Dr. Colin Lenington Tags: MS, MultipleSclerosis, MSResearch, MSSociety, RealTalkMS Privacy Policy

Go online to PeerView.com/QQN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses the current clinical data and practical application of disease-modifying therapies in the management of patients with spinal muscular atrophy. Upon completion of this activity, participants should be better able to: Identify spinal muscular atrophy (SMA) through newborn screening and/or recognition of symptoms and signs, Apply current evidence on the efficacy, safety, and tolerability of approved disease-modifying therapies in the treatment of SMA, Counsel caregivers and/or patients regarding the need for monitoring and supportive care to optimize treatment outcomes in SMA.

Go online to PeerView.com/QQN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses the current clinical data and practical application of disease-modifying therapies in the management of patients with spinal muscular atrophy. Upon completion of this activity, participants should be better able to: Identify spinal muscular atrophy (SMA) through newborn screening and/or recognition of symptoms and signs, Apply current evidence on the efficacy, safety, and tolerability of approved disease-modifying therapies in the treatment of SMA, Counsel caregivers and/or patients regarding the need for monitoring and supportive care to optimize treatment outcomes in SMA.

Go online to PeerView.com/QQN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses the current clinical data and practical application of disease-modifying therapies in the management of patients with spinal muscular atrophy. Upon completion of this activity, participants should be better able to: Identify spinal muscular atrophy (SMA) through newborn screening and/or recognition of symptoms and signs, Apply current evidence on the efficacy, safety, and tolerability of approved disease-modifying therapies in the treatment of SMA, Counsel caregivers and/or patients regarding the need for monitoring and supportive care to optimize treatment outcomes in SMA.

Go online to PeerView.com/QQN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses the current clinical data and practical application of disease-modifying therapies in the management of patients with spinal muscular atrophy. Upon completion of this activity, participants should be better able to: Identify spinal muscular atrophy (SMA) through newborn screening and/or recognition of symptoms and signs, Apply current evidence on the efficacy, safety, and tolerability of approved disease-modifying therapies in the treatment of SMA, Counsel caregivers and/or patients regarding the need for monitoring and supportive care to optimize treatment outcomes in SMA.

Go online to PeerView.com/QQN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses the current clinical data and practical application of disease-modifying therapies in the management of patients with spinal muscular atrophy. Upon completion of this activity, participants should be better able to: Identify spinal muscular atrophy (SMA) through newborn screening and/or recognition of symptoms and signs, Apply current evidence on the efficacy, safety, and tolerability of approved disease-modifying therapies in the treatment of SMA, Counsel caregivers and/or patients regarding the need for monitoring and supportive care to optimize treatment outcomes in SMA.

Go online to PeerView.com/QQN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses the current clinical data and practical application of disease-modifying therapies in the management of patients with spinal muscular atrophy. Upon completion of this activity, participants should be better able to: Identify spinal muscular atrophy (SMA) through newborn screening and/or recognition of symptoms and signs, Apply current evidence on the efficacy, safety, and tolerability of approved disease-modifying therapies in the treatment of SMA, Counsel caregivers and/or patients regarding the need for monitoring and supportive care to optimize treatment outcomes in SMA.

Go online to PeerView.com/QQN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses the current clinical data and practical application of disease-modifying therapies in the management of patients with spinal muscular atrophy. Upon completion of this activity, participants should be better able to: Identify spinal muscular atrophy (SMA) through newborn screening and/or recognition of symptoms and signs, Apply current evidence on the efficacy, safety, and tolerability of approved disease-modifying therapies in the treatment of SMA, Counsel caregivers and/or patients regarding the need for monitoring and supportive care to optimize treatment outcomes in SMA.

Go online to PeerView.com/QQN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses the current clinical data and practical application of disease-modifying therapies in the management of patients with spinal muscular atrophy. Upon completion of this activity, participants should be better able to: Identify spinal muscular atrophy (SMA) through newborn screening and/or recognition of symptoms and signs, Apply current evidence on the efficacy, safety, and tolerability of approved disease-modifying therapies in the treatment of SMA, Counsel caregivers and/or patients regarding the need for monitoring and supportive care to optimize treatment outcomes in SMA.

Go online to PeerView.com/MUD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on the management of multiple sclerosis (MS) in women discusses current perspectives on the treatment of MS in women of childbearing age, including the appropriate use of disease-modifying therapies (DMTs) before, during, and after pregnancy. Upon completion of this activity, participants should be better able to: Apply current guidelines, expert recommendations, and evidence for the management of MS in women before, during, and after pregnancy, Describe the influence of MS on pregnancy (eg, pregnancy outcomes) and of pregnancy on MS (eg, disease progression), Assess the safety and efficacy of disease-modifying therapies (DMTs) before, during, and after pregnancy in women with MS, Incorporate shared decision-making strategies to personalize care of women with MS throughout their family planning journey.

Go online to PeerView.com/MUD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on the management of multiple sclerosis (MS) in women discusses current perspectives on the treatment of MS in women of childbearing age, including the appropriate use of disease-modifying therapies (DMTs) before, during, and after pregnancy. Upon completion of this activity, participants should be better able to: Apply current guidelines, expert recommendations, and evidence for the management of MS in women before, during, and after pregnancy, Describe the influence of MS on pregnancy (eg, pregnancy outcomes) and of pregnancy on MS (eg, disease progression), Assess the safety and efficacy of disease-modifying therapies (DMTs) before, during, and after pregnancy in women with MS, Incorporate shared decision-making strategies to personalize care of women with MS throughout their family planning journey.

Go online to PeerView.com/MUD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on the management of multiple sclerosis (MS) in women discusses current perspectives on the treatment of MS in women of childbearing age, including the appropriate use of disease-modifying therapies (DMTs) before, during, and after pregnancy. Upon completion of this activity, participants should be better able to: Apply current guidelines, expert recommendations, and evidence for the management of MS in women before, during, and after pregnancy, Describe the influence of MS on pregnancy (eg, pregnancy outcomes) and of pregnancy on MS (eg, disease progression), Assess the safety and efficacy of disease-modifying therapies (DMTs) before, during, and after pregnancy in women with MS, Incorporate shared decision-making strategies to personalize care of women with MS throughout their family planning journey.

Go online to PeerView.com/MUD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on the management of multiple sclerosis (MS) in women discusses current perspectives on the treatment of MS in women of childbearing age, including the appropriate use of disease-modifying therapies (DMTs) before, during, and after pregnancy. Upon completion of this activity, participants should be better able to: Apply current guidelines, expert recommendations, and evidence for the management of MS in women before, during, and after pregnancy, Describe the influence of MS on pregnancy (eg, pregnancy outcomes) and of pregnancy on MS (eg, disease progression), Assess the safety and efficacy of disease-modifying therapies (DMTs) before, during, and after pregnancy in women with MS, Incorporate shared decision-making strategies to personalize care of women with MS throughout their family planning journey.

Go online to PeerView.com/MUD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on the management of multiple sclerosis (MS) in women discusses current perspectives on the treatment of MS in women of childbearing age, including the appropriate use of disease-modifying therapies (DMTs) before, during, and after pregnancy. Upon completion of this activity, participants should be better able to: Apply current guidelines, expert recommendations, and evidence for the management of MS in women before, during, and after pregnancy, Describe the influence of MS on pregnancy (eg, pregnancy outcomes) and of pregnancy on MS (eg, disease progression), Assess the safety and efficacy of disease-modifying therapies (DMTs) before, during, and after pregnancy in women with MS, Incorporate shared decision-making strategies to personalize care of women with MS throughout their family planning journey.

Go online to PeerView.com/MUD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on the management of multiple sclerosis (MS) in women discusses current perspectives on the treatment of MS in women of childbearing age, including the appropriate use of disease-modifying therapies (DMTs) before, during, and after pregnancy. Upon completion of this activity, participants should be better able to: Apply current guidelines, expert recommendations, and evidence for the management of MS in women before, during, and after pregnancy, Describe the influence of MS on pregnancy (eg, pregnancy outcomes) and of pregnancy on MS (eg, disease progression), Assess the safety and efficacy of disease-modifying therapies (DMTs) before, during, and after pregnancy in women with MS, Incorporate shared decision-making strategies to personalize care of women with MS throughout their family planning journey.

Go online to PeerView.com/MUD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on the management of multiple sclerosis (MS) in women discusses current perspectives on the treatment of MS in women of childbearing age, including the appropriate use of disease-modifying therapies (DMTs) before, during, and after pregnancy. Upon completion of this activity, participants should be better able to: Apply current guidelines, expert recommendations, and evidence for the management of MS in women before, during, and after pregnancy, Describe the influence of MS on pregnancy (eg, pregnancy outcomes) and of pregnancy on MS (eg, disease progression), Assess the safety and efficacy of disease-modifying therapies (DMTs) before, during, and after pregnancy in women with MS, Incorporate shared decision-making strategies to personalize care of women with MS throughout their family planning journey.

Go online to PeerView.com/MUD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on the management of multiple sclerosis (MS) in women discusses current perspectives on the treatment of MS in women of childbearing age, including the appropriate use of disease-modifying therapies (DMTs) before, during, and after pregnancy. Upon completion of this activity, participants should be better able to: Apply current guidelines, expert recommendations, and evidence for the management of MS in women before, during, and after pregnancy, Describe the influence of MS on pregnancy (eg, pregnancy outcomes) and of pregnancy on MS (eg, disease progression), Assess the safety and efficacy of disease-modifying therapies (DMTs) before, during, and after pregnancy in women with MS, Incorporate shared decision-making strategies to personalize care of women with MS throughout their family planning journey.

Barbara S. Giesser, MD, FAAN, FANA, is an internationally recognized clinician and award-winning educator who has specialized in the care of persons with Multiple Sclerosis since 1982. Her approach to the diagnosis and management of persons with MS combines advanced diagnostics and a personalized medication plan for each patient with an emphasis on integrating lifestyle and wellness strategies into the neurologic treatment plan. Learn about disease modifying therapies for the treatment of Multiple Sclerosis in this PNI Minute. For more information: (310) 582-7613 | pacificbrainhealth.org

Dr. Jose Posas, a sports neurologist at Ochsner Clinic Foundation, discusses his recent NeuroByte entitled, "Multiple Sclerosis Management: First-line Disease-Modifying Therapies". Show references: https://learning.aan.com/diweb/catalog/item?id=5204492

Disease-modifying therapies are the cornerstone of any effective MS treatment plan. But with more than 20 approved prescription medications available today, the choices can seem overwhelming.   People living with MS have questions -- Do you start out with a safe but less effective medication, or do you hit MS hard with a high-efficacy drug that may carry more risks? When is the right time to consider switching medications, and how do you have that conversation with your neurologist? Do things like other health conditions affect which disease-modifying therapy you're on? And what about aging?    My guest is Dr. Scott Newsome, an Associate Professor of Neurology, and Director of Neurosciences Consultation and Infusion Center at Johns Hopkins Medicine. Dr. Newsome also serves as the Co-Director of the Multiple Sclerosis Experimental Therapeutics Program at Johns Hopkins.  And I'm devoting this entire episode of RealTalk MS to taking a deep-dive into disease-modifying therapies with Dr. Newsome.   We'll also give you the details about two major events taking place this week -- the MSVirtual2020 conference and the Keep Moving Forward benefit celebrating the MS Movement.   We have a lot to talk about! Are you ready for RealTalk MS??! ECTRIMS + ACTRIMS = MSVirtual2020  :24 Don't miss Keep Moving Forward  1:08 My Interview with Dr. Scott Newsome  1:38 Share this episode  33:06 Leave a rating & review  33:26 Please Support the National MS Society COVID-19 Response Fund  34:45 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email:  realtalkms.com/158 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.comPhone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Give RealTalk MS a Rating and Review National MS Society's Ask An MS Expert Video Replay National MS Society COVID-19 Response Fund Join the RealTalk MS Facebook Group Download the RealTalk MS App for iOS Download the RealTalk MS App for Android Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 158 Hosted By: Jon Strum Guests: Dr. Scott Newsome Tags: MS, MultipleSclerosis, MSResearch, MSSociety, Tecfidera, Ocrevus, Kesimpta, Copaxone, Gilenya, RealTalkMS Privacy Policy    

The guidance for using MS disease-modifying therapies during the COVID-19 pandemic has been updated. My guest is Dr. Aaron Miller, the Chair of the National MS Society’s National Medical Advisory Committee, the Medical Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis, and a Professor of Neurology at the Icahn School of Medicine at Mount Sinai, and we're talking about the new guidance for each and every MS disease-modifying therapy that's currently available.     Last week, in the middle of the night, protections for people with pre-existing health conditions came under attack. We'll let you know what it all means and what's at stake for every person in the U.S. living with MS.   We're also talking about the results of a study that show more people than ever are exploring alternative medicine in managing their MS symptoms. And we'll tell you about a new online MS Treatment Adherence Resource Center.   In last week's International Progressive MS Alliance global webcast, 3 top MS experts shared very encouraging news about the development of new life-changing treatments for progressive MS. We'll let you know where to find the video replay of the webcast. And while you're checking online video replays, we'll let you know where you can find a replay of the Consortium of Multiple Sclerosis Centers' virtual Patient Education Program.   We have a lot to talk about! Are you ready for RealTalk MS??! In a late-night brief, the Trump administration asks the Supreme Court to invalidate Obamacare and eliminate protections for people with pre-existing health conditions  1:24 Catch the video replay of the International Progressive MS Alliance global webcast  6:04 Catch the video replay of the CMSC Patient Education Program    7:34 Survey says...Alternative medicine is widespread among people living with MS  8:19 MS Treatment Adherence Resource Center is launched  11:03 My Interview with Dr. Aaron Miller  13:06 Share this episode  23:26 Please Support the National MS Society COVID-19 Response Fund  23:45 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/148 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.comPhone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com National MS Society's Ask An MS Expert Video Replay What You Need to Know About Coronavirus (COVID-19) National MS Society COVID-19 Response Fund Video Replay: International Progressive MS Alliance Webcast Video Replay: Consortium of MS Centers Patient Education Program STUDY: Cross-Sectional Survey of Complementary and Alternative Medicine Used in Oregon and Southwest Washington to Treat Multiple Sclerosis: A 17-Year Update MS Treatment Adherence Resource Center Join the RealTalk MS Facebook Group Download the RealTalk MS App for iOS Download the RealTalk MS App for Android Give RealTalk MS a Rating and Review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 148 Hosted By: Jon Strum Guests: Dr. Aaron Miller Tags: MS, MultipleSclerosis, MSResearch, MSSociety, COVID19, RealTalkMS Privacy Policy

MS News Today columnist and forums moderator Ed Tobias discusses the impact of the noval coronavirus on people with MS who are using disease-modifying therapies. Are you interested in learning more about Multiple Sclerosis? If so, please visit https://multiplesclerosisnewstoday.com/

The National MS Society's National Medical Advisory Committee has issued its recommendations for MS disease-modifying therapies and the coronavirus (COVID-19), and we're sharing them in this episode. You'll also hear about a new disease-modifying therapy that's about to receive FDA approval. We'll tell you about a clinical trial for a potential disease-modifying therapy for progressive MS that fell short of achieving its goals. And you'll hear about study results that indicate there are still a lot of people living with MS who aren't acting in their own best interest.   My guest this week is Dawnia Baynes. Besides being an MS Activist, Dawnia facilitates a very special MS support group, and last month, the Southern-California Nevada Chapter of the National MS Society named Dawnia their Inspirational Person of the Year. We have a lot to talk about! Are you ready for RealTalk MS??! ___________   Make sure you're getting your COVID-19 info from credible sources   :39 The Coronavirus (COVID-19) and MS Disease-Modifying Therapies  2:41 Ozanimod scheduled for FDA Approval this Month  2:09 High-Dose Biotin For Progressive MS Fails to Improve Disability  7:41 Disease-Modifying Therapy Non-Compliance Among People Living with MS  9:07 My Interview with Dawnia Baynes  12:05 Share this Episode  24:26 Reminder...Please Donate to Walk-MS  24:46 ___________ SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/133 ___________ ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.comPhone: (310) 526-2283 ___________ LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com What You Need to Know About Coronavirus (COVID-19) MS Disease-Modifying Treatment Guidelines for Coronavirus (COVID-19) Non-Compliance With Disease-Modifying Therapies in Patients With Multiple Sclerosis: A Qualitative Analysis Support Group for Teens Living with MS  Jon's WALK-MS Fundraising Page Download the RealTalk MS App for iOS Download the RealTalk MS App for Android Give RealTalk MS a Rating & Review ___________ Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 133 Hosted By: Jon Strum Guests: Dawnia Baynes Tags: MS, MultipleSclerosis, MSResearch, MSActivist, MSSociety, Coronavirus, COVID-19, RealTalkMS Privacy Policy

Five years ago, James Beard Award-winning chef Chris Shepherd decided to hold a barbecue event in his restaurant's parking lot, to raise money for the National MS Society. Today, the Southern Smoke Festival has grown into the largest 3rd party MS Society fundraising event in the United States, and with the 5th Annual Southern Smoke Festival just a few weeks away, we're talking with Chris about how this event got its start, and how it's grown to be one of the most noteworthy culinary events in the country.      We're also talking about the new vaccination guidelines (including flu shots!) that were just published by the American Academy of Neurology for people living with MS. We'll tell you about a study that gives you one more reason to start disease-modifying therapy early...and stay on it! We'll also tell you about a study that shows the cost of MS disease-modifying therapy has increased 7X over just 10 years for Medicare patients. And we've found one more study that demonstrates how people with more advanced progressive MS can still benefit from physical rehabilitation.   We have a lot to talk about! Are you ready for RealTalk MS??! ___________   Where You Can Find Me in September  :32 American Academy of Neurology Issues Vaccination Guidelines for People Living with MS   4:39 The Long-Term Effects of Disease-Modifying Therapy   6:15 DMT Costs Increase 7X for Medicare Patients  7:49 Upper-Limb Task-Oriented Rehab Shows Benefits for People Living with Progressive MS  11:56 My Interview with Chris Shepherd  15:01 Subscribe to RealTalk MS or Just Ask Alexa  27:13 ___________ ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.comPhone: (310) 526-2283 ___________ LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Give RealTalk MS a Rating & Review  Southern Smoke Festival Practice Guideline Update Summary: Vaccine-Preventable Infections and Immunization in Multiple Sclerosis -- Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology The Long-Term Effects of Disease-Modifying Therapies on Disability in People Living with Multiple Sclerosis: A Systematic Review and Meta-Analysis Trends in Prices, Market Share, and Spending on Self-Administered Disease-Modifying Therapies for Multiple Sclerosis in Medicare Part D Preserved Brain Functional Plasticity After Upper Limb Task-Oriented Rehabilitation in Progressive Multiple Sclerosis Give RealTalk MS a Rating & Review  Download the RealTalk MS App for iOS Download the RealTalk MS App for Android ___________ Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 105 Hosted By: Jon Strum Guest: Chris Shepherd Tags: MS, MultipleSclerosis, MSResearch, MSSociety, SouthernSmokeTX, RealTalkMS

Go online to PeerView.com/ECH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in the treatment of multiple sclerosis reviews updates from the 2019 annual meeting of the American Academy of Neurology in Philadelphia, including new data on approved oral disease-modifying therapies, approved monoclonal antibodies, and selected emerging therapies. Upon completion of this activity, participants should be better able to: Apply new data on the efficacy, safety, and tolerability of approved disease-modifying therapies when managing patients with multiple sclerosis, Cite recently presented data related to emerging disease-modifying therapies for the treatment of multiple sclerosis, Identify the potential clinical impact investigational disease-modifying therapies may have on the future management of multiple sclerosis.

Go online to PeerView.com/ECH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in the treatment of multiple sclerosis reviews updates from the 2019 annual meeting of the American Academy of Neurology in Philadelphia, including new data on approved oral disease-modifying therapies, approved monoclonal antibodies, and selected emerging therapies. Upon completion of this activity, participants should be better able to: Apply new data on the efficacy, safety, and tolerability of approved disease-modifying therapies when managing patients with multiple sclerosis, Cite recently presented data related to emerging disease-modifying therapies for the treatment of multiple sclerosis, Identify the potential clinical impact investigational disease-modifying therapies may have on the future management of multiple sclerosis.

Go online to PeerView.com/ECH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in the treatment of multiple sclerosis reviews updates from the 2019 annual meeting of the American Academy of Neurology in Philadelphia, including new data on approved oral disease-modifying therapies, approved monoclonal antibodies, and selected emerging therapies. Upon completion of this activity, participants should be better able to: Apply new data on the efficacy, safety, and tolerability of approved disease-modifying therapies when managing patients with multiple sclerosis, Cite recently presented data related to emerging disease-modifying therapies for the treatment of multiple sclerosis, Identify the potential clinical impact investigational disease-modifying therapies may have on the future management of multiple sclerosis.

Go online to PeerView.com/ECH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in the treatment of multiple sclerosis reviews updates from the 2019 annual meeting of the American Academy of Neurology in Philadelphia, including new data on approved oral disease-modifying therapies, approved monoclonal antibodies, and selected emerging therapies. Upon completion of this activity, participants should be better able to: Apply new data on the efficacy, safety, and tolerability of approved disease-modifying therapies when managing patients with multiple sclerosis, Cite recently presented data related to emerging disease-modifying therapies for the treatment of multiple sclerosis, Identify the potential clinical impact investigational disease-modifying therapies may have on the future management of multiple sclerosis.

Go online to PeerView.com/ECH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in the treatment of multiple sclerosis reviews updates from the 2019 annual meeting of the American Academy of Neurology in Philadelphia, including new data on approved oral disease-modifying therapies, approved monoclonal antibodies, and selected emerging therapies. Upon completion of this activity, participants should be better able to: Apply new data on the efficacy, safety, and tolerability of approved disease-modifying therapies when managing patients with multiple sclerosis, Cite recently presented data related to emerging disease-modifying therapies for the treatment of multiple sclerosis, Identify the potential clinical impact investigational disease-modifying therapies may have on the future management of multiple sclerosis.

Go online to PeerView.com/ECH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in the treatment of multiple sclerosis reviews updates from the 2019 annual meeting of the American Academy of Neurology in Philadelphia, including new data on approved oral disease-modifying therapies, approved monoclonal antibodies, and selected emerging therapies. Upon completion of this activity, participants should be better able to: Apply new data on the efficacy, safety, and tolerability of approved disease-modifying therapies when managing patients with multiple sclerosis, Cite recently presented data related to emerging disease-modifying therapies for the treatment of multiple sclerosis, Identify the potential clinical impact investigational disease-modifying therapies may have on the future management of multiple sclerosis.

Go online to PeerView.com/ECH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in the treatment of multiple sclerosis reviews updates from the 2019 annual meeting of the American Academy of Neurology in Philadelphia, including new data on approved oral disease-modifying therapies, approved monoclonal antibodies, and selected emerging therapies. Upon completion of this activity, participants should be better able to: Apply new data on the efficacy, safety, and tolerability of approved disease-modifying therapies when managing patients with multiple sclerosis, Cite recently presented data related to emerging disease-modifying therapies for the treatment of multiple sclerosis, Identify the potential clinical impact investigational disease-modifying therapies may have on the future management of multiple sclerosis.

Go online to PeerView.com/ECH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in the treatment of multiple sclerosis reviews updates from the 2019 annual meeting of the American Academy of Neurology in Philadelphia, including new data on approved oral disease-modifying therapies, approved monoclonal antibodies, and selected emerging therapies. Upon completion of this activity, participants should be better able to: Apply new data on the efficacy, safety, and tolerability of approved disease-modifying therapies when managing patients with multiple sclerosis, Cite recently presented data related to emerging disease-modifying therapies for the treatment of multiple sclerosis, Identify the potential clinical impact investigational disease-modifying therapies may have on the future management of multiple sclerosis.

Dr. Robert H. Gross discusses disease-modifying therapies in MS in the third part of a three-part series. To learn more, read the article "Monitoring, Switching, and Stopping Multiple Sclerosis Disease-Modifying Therapies" by Dr. Gross and Dr. John Corboy in the June 2019 Multiple Sclerosis and Other CNS Inflammatory Diseases issue of Continuum. 

Dr. Robert H. Gross discusses disease-modifying therapies in MS in the second part of a three-part series. To learn more, read the article "Monitoring, Switching, and Stopping Multiple Sclerosis Disease-Modifying Therapies" by Dr. Gross and Dr. John Corboy in the June 2019 Multiple Sclerosis and Other CNS Inflammatory Diseases issue of Continuum. 

Dr. Robert H. Gross discusses disease-modifying therapies in MS in the first part of a three-part series. To learn more, read the article "Monitoring, Switching, and Stopping Multiple Sclerosis Disease-Modifying Therapies" by Dr. Gross and Dr. John Corboy in the June 2019 Multiple Sclerosis and Other CNS Inflammatory Diseases issue of Continuum. 

In this episode, we discuss John’s Rule #2 - movement is life. Rule #1 was discussed in episode #2 and Rule #1a (Disease Modifying Therapies) was the topic of conversation in episode #3. We share the importance of movement for individuals living with MS and the benefits and we chat about the Exercising Your Options article in the Winter 2018 - 2019 edition of Momentum, as well.

Our guest today on The FUMS Podcast Show is Stephen Camp, the President and Founder of Avior Nutritionals. Avior Nutritionals is the company behind Myetin, which has been mentioned previously both on the FUMSnow blog and on the podcast. Myetin is an oral supplement which can help people experiencing nerve damage, so it is obviously an exciting option for people with MS. It works to support the body’s nutritional deficiencies at a cellular level and is the only product that has both NAD+ and Biotin as active ingredients. Here comes the science bit! Biotin is a water-soluble B vitamin, which is involved in a wide range of metabolic processes, primarily related to the utilization of fats, carbohydrates, and amino acids. NAD+,or nicotinamide adenine dinucleotide, is a coenzyme found in all living cells, and it's required for the fundamental biological processes that make life possible. Topics covered include: How Myetin can support and strengthen the body at a cellular level What the benefits are for people with chronic illnesses, including MS How Myetin can work alongside Disease Modifying Therapies to support people with MS Stories from people with MS who are taking Myetin The Myetin 90 Day Challenge!   Resources mentioned in this episode (clickable links): Myetin on the FUMS podcast and blog Avior Nutritionals website Avior Nutritionals on Facebook Avior Nutritionals on Twitter Avior Nutritionals on Instagram Where to go to learn more about or order Myetin ** Sign up for the FUMS Friday Night 6 Pack at FUMSnow.com. And for more information about Patients Getting Paid, please visit FUMSnow.com/PatientsGettingPaid. **If you get value from the FUMSnow Podcast Show, please consider leaving a rating or review wherever you get your podcasts. Reviews are really important and help to spread the word about what we do. It's quick and easy to do and we have some instructions here. Thanks for your time and support! **Don’t forget to join us on the FUMS Facebook Pageand on Twitter at FUMS. Have an idea for a topic or someone to interview? Perhaps YOU?? Send me an email at Kathy@FUMSnow.com. And remember to speak to this stupid disease as it deserves: tell it FUMS every day!!

George Pepper was diagnosed with multiple sclerosis in 2009, at the age of 22. He initially found it difficult to connect with others his own age who were living with MS, so George set up a website where people living with MS could meet and share their experiences. That website evolved into an online community called shift.ms, and today, more than 18,000 people participate in the shift.ms community. My guests today are the founder of shift.ms, George Pepper, and Aoife Kirwan, a member of the shift.ms community.      We're also talking about a new report that reminds us that there's a lot of fake health news online, how Medicare rules are costing people living with MS more money, a global response to talking about sex and MS, and a study that will introduce you to the Caregiver Strain Index, a reliable tool in measuring MS caregiver burden.   We have a lot to talk about! Are you ready for RealTalk MS?! ___________ A solution to Loneliness & MS   :23 Study Results Warn Against "Fake Online Health News"  2:48 Medicare Policies Cost People With MS More Money  8:50 MS International Federation Talks About Sex & MS  12:57 Caregiver Strain Index Is A Valid Measurement of Caregiver Burden  14:33 My Interview with George Pepper & Aoife Kirwan  18:24 Join The RealTalk MS Conversation  30:25 ___________ ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jonstrum@RealTalkMS.com Phone: (310) 526-2283 ___________ LINKSIf your podcast app doesn’t allow you to click on these links, you’ll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Download the RealTalk MS App for iOS Download the RealTalk MS App for Android Give RealTalk MS a Rating & Review The Most Popular Health Articles of 2018: A Scientific Credibility Review Trends in Coverage for Disease-Modifying Therapies for Multiple Sclerosis in Medicare Part D Sex Life & MS Measuring Burden in Caregivers of People with Multiple Sclerosis: Psychometric Properties of the CSI Questionnaire Shift.ms ___________ Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 77 Hosted By: Jon Strum Guest: George Pepper & Aoife Kirwan Tags: MS, MultipleSclerosis, MSResearch, Caregiving, ShiftMS, MSIntFederation, RealTalkMS

Taking Stock of Late-Breaking Data on Disease-Modifying Therapies for Multiple Sclerosis: What Are the Key Learnings From Berlin?

Taking Stock of Late-Breaking Data on Disease-Modifying Therapies for Multiple Sclerosis: What Are the Key Learnings From Berlin?

Taking Stock of Late-Breaking Data on Disease-Modifying Therapies for Multiple Sclerosis: What Are the Key Learnings From Berlin?

Taking Stock of Late-Breaking Data on Disease-Modifying Therapies for Multiple Sclerosis: What Are the Key Learnings From Berlin?

Taking Stock of Late-Breaking Data on Disease-Modifying Therapies for Multiple Sclerosis: What Are the Key Learnings From Berlin?

Taking Stock of Late-Breaking Data on Disease-Modifying Therapies for Multiple Sclerosis: What Are the Key Learnings From Berlin?

Taking Stock of Late-Breaking Data on Disease-Modifying Therapies for Multiple Sclerosis: What Are the Key Learnings From Berlin?

Taking Stock of Late-Breaking Data on Disease-Modifying Therapies for Multiple Sclerosis: What Are the Key Learnings From Berlin?

In this episode, the topic of conversation is disease modifying therapies (DMT). We share the importance of DMT's as well as touch upon complementary therapies.

Ilya Kister, MD, from NYU Langone Health in New York City, discusses his research into the predictors of multiple sclerosis relapse and disability progression in patients who stop disease-modifying therapies.

Presented at NACFC Anaheim 2011 this symposium presentation offers information on the current treatment options for patients with cystic fibrosis. Mike Boyle, MD, from Johns Hopkins University School of Medicine offers a 25-minute look at the basics of CF, then describes genotype and CF phenotype relationships. The presentation includes a review the influences of severity of lung disease and outcomes in CF, followed up by issues related to adherence.

Presented at NACFC Anaheim 2011 this symposium presentation offers information on the current treatment options for patients with cystic fibrosis. Mike Boyle, MD, from Johns Hopkins University School of Medicine offers a 25-minute look at the basics of CF, then describes genotype and CF phenotype relationships. The presentation includes a review the influences of severity of lung disease and outcomes in CF, followed up by issues related to adherence.

Presented at NACFC Anaheim 2011 this symposium presentation offers information on the current treatment options for patients with cystic fibrosis. Mike Boyle, MD, from Johns Hopkins University School of Medicine offers a 25-minute look at the basics of CF, then describes genotype and CF phenotype relationships. The presentation includes a review the influences of severity of lung disease and outcomes in CF, followed up by issues related to adherence.

Presented at NACFC Anaheim 2011 this symposium presentation offers information on the current treatment options for patients with cystic fibrosis. Mike Boyle, MD, from Johns Hopkins University School of Medicine offers a 25-minute look at the basics of CF, then describes genotype and CF phenotype relationships. The presentation includes a review the influences of severity of lung disease and outcomes in CF, followed up by issues related to adherence.

Presented at NACFC Anaheim 2011 this symposium presentation offers information on the current treatment options for patients with cystic fibrosis. Mike Boyle, MD, from Johns Hopkins University School of Medicine offers a 25-minute look at the basics of CF, then describes genotype and CF phenotype relationships. The presentation includes a review the influences of severity of lung disease and outcomes in CF, followed up by issues related to adherence.

Presented at NACFC Anaheim 2011 this symposium presentation offers information on the current treatment options for patients with cystic fibrosis. Mike Boyle, MD, from Johns Hopkins University School of Medicine offers a 25-minute look at the basics of CF, then describes genotype and CF phenotype relationships. The presentation includes a review the influences of severity of lung disease and outcomes in CF, followed up by issues related to adherence.